Dr. Wang works on biomarker identification using multiparametric magnetic resonance imaging and homo- and hetero-nuclear spectroscopy techniques for pediatric disease research including tumors, iron overload, cystic fibrosis, muscular dystrophy, autism, mitochondrial, Gaucher’s, and Canavan’s diseases.
Dr. Roberts investigates brain-wave scanning with magnetoencephalography (MEG) and works to identify biomarkers for neuropsychiatric disorders like autism. Those biomarkers are for diagnosis, prognosis, stratification, and response monitoring as well as substrate identification for targeted therapy. Putting the "bio" into biomarkers is a major emphasis of Dr. Roberts' research, for which he uses advanced diffusion magnetic resonance imaging (MRI) and edited spectroscopy.
Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.
Dr. Hartung's clinical and translational research program focuses on autosomal recessive polycystic kidney disease and other genetic kidney diseases, development of new kidney and liver imaging biomarkers, and neurocognitive outcomes in children with chronic kidney disease.
Dr. McGrath-Morrow is associate chief of the Division of Pulmonary and Sleep Medicine and leader of the Post-preemie Lung Disease Clinic at Children’s Hospital of Philadelphia. Her research seeks to link early life events with adult lung health and biomarker discovery for future trials.
Dr. Srinivasan is an attending neonatologist with the Pediatric Sepsis Program and the Division of Neonatology at Children's Hospital of Philadelphia. Her research focuses on biomarkers in neonatal inflammation and infection; and improving prediction, recognition and management of neonatal infections.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. Nadir Yehya is interested in all aspects of mechanical ventilation and respiratory failure in children, including pre-clinical models, ventilator-induced lung injury, and acute respiratory distress syndrome.